Company Profile
ADR120S researches, develops, produces, and sells cell therapy related medical devices in Japan. The company sells cell therapy kits, as well as engages in the R&D of cell therapy technology, etc. Its products pipeline includes ECCI-50 for the treatment of male stress urinary incontinence.
Its portfolio also includes ECCL-50 to treat liver cirrhosis, and Cyt-006 to prevent postoperative adhesion for primary rectal cancer. The company is also conducting clinical trials/research on cell therapy for a range of diseases and applications
Including anterior cruciate ligament repair, bone repair, burn scars, chronic wound healing, critical limb ischemia, anal and Crohn's disease fistulas, erectile dysfunction, meniscus repair, stress urinary incontinence scleroderma, vocal cord repair, liver cirrhosis, etc. Additionally, it invests in, owns, develops, leases, and manages real estate projects and hotels
Provides real estate brokerage services. Incorporated in 2004 and headquartered in Chiyoda, Japan, ADR120S was formerly known as Cytori Cell Research Institute, Inc. before rebranding in July 2025.